Healthcare
Kodiak Sciences Inc.(KOD)
Live Price
Offline$36.63
+1.36% today
1Y Change
+792.68%
Window
Jun 25, 2025 β Jun 16, 2026
- Market Cap
- $2.34B
- Revenue Growth
- 0.0%
- EPS Growth
- -29.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars Β· Jun 25, 2025 β Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kodiak Sciences Inc. (KOD) is a Healthcare stock with a market cap of $2.34B and listed on NASDAQ. The stock last traded around $36.63 and up 792.7% across the available one-year price window (Jun 25, 2025 β Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -29.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -29.0%, free cash flow -16.0% with operating margin 0.0% and ROIC -73.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines KOD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -29.0%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | β | -2.3% | -8.6% | -14.2% |
2026 Mar 31, 2026 | -2.0% | +12.3% | +9.7% | +14.6% |
2025 Nov 13, 2025 | -8.4% | +3.4% | +3.8% | +26.2% |
Benchmark Edge
KOD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KOD
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KOD Max Drawdown
-36.24%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KOD and SPY.
Company Overview
Kodiak Sciences Inc.
NASDAQ Global Market
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naΓ―ve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
- Leadership
- Victor Perlroth
- IPO Date
- Oct 4, 2018
- Employees
- 109
- Street Address
- 1200 Page Mill Road
- Mailing
- Palo Alto, CA, 94304
- Region
- Palo Alto, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 281 0850
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- β
- Price/Book
- 15.0
Growth
- Revenue
- 0.0%
- EPS
- -29.0%
- Free Cash Flow
- -16.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -255.4%
- ROIC
- -73.7%
Balance Sheet
- Debt/Equity
- 0.38
- Current Ratio
- 4.72
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.